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Abstract Insulin resistance and the metabolic syndrome are
complexmetabolic traits andkey risk factors for thedevelopment
of cardiovascular disease. They result from the interplay of envi-
ronmental and genetic factors but the full extent of the genetic
background to these conditions remains incomplete. Large-scale
genome-wide association studies have helped advance the iden-
tification of common genetic variation associated with insulin
resistanceand themetabolic syndrome,andmore recently, exome
sequencing has allowed the identification of rare variants associ-
ated with the pathogenesis of these conditions. Many variants
associatedwith insulin resistance are directly involved in glucose
metabolism;however, functionalstudiesare required toassess the
contribution of other variants to the development of insulin resis-
tance. Many genetic variants involved in the pathogenesis of the
metabolic syndrome are associatedwith lipidmetabolism.
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Introduction
Both insulin resistance and the metabolic syndrome are pow-
erful risk factors for the development of cardiovascular
disease and type 2 diabetes (T2D). Insulin resistance can be
defined as the inability of insulin to stimulate glucose dispos-
al, and when an insulin-resistant individual is unable to secrete
sufficient insulin to overcome this defect, T2D develops. The
metabolic syndrome comprises a number of risk factors which
occur together more often than by chance alone. A joint sci-
entific statement issued in 2009 by the World Health
Organisation (WHO), International Diabetes Federation
(IDF), American Heart Association (AHA) and National
Heart, Lung and Blood Institute (NHLBI) identified the met-
abolic syndrome as comprising hypertension, dyslipidaemia
(raised triglyceride and low high-density lipoprotein choles-
terol levels), hyperglycaemia and central obesity [1].
The prevalence of insulin resistance and the metabolic syn-
drome is increasing, particularly in developing countries and
in younger populations with estimates of prevalence ranging
from 20 to 40% in different populations [2–4].While there are
strong lifestyle determinants for the development of both in-
sulin resistance and the metabolic syndrome, it is increasingly
clear that an individual’s risk of developing insulin resistance
and aspects of the metabolic syndrome are also determined by
genetic factors. Early familial genetic studies provided strong
evidence for a genetic basis for both insulin resistance and the
individual components of the metabolic syndrome [5–11], and
since then, genome-wide association studies (GWAS) and,
more recently, next-generation sequencing, have allowed for
the identification of both common (defined by a minor allele
frequency (MAF) >5 %) and rare (MAF < 0.5 %) genetic var-
iants linked with these disease-associated traits. Associations
of common genetic variation with a particular trait are gener-
ally defined with a genome-wide significance level of p < 5 ×
10−8. The scope of this review is to summarise some of the
genome-wide association studies (GWAS) studies and meta-
analyses performed in relation to insulin resistance and the
metabolic syndrome.
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Common Genetic Variation in Insulin Resistance
Since 2007, genome-wide association studies (GWAS) have
identified approximately 88 loci associated with risk of devel-
oping T2D [12]. The vast majority of the loci related to T2D
are primarily associated with insulin secretion andβ-cell func-
tion with far fewer variants apparently influencing insulin re-
sistance. There are a number of reasons for this, not the least
that insulin resistance is strongly linked to obesity, and dis-
secting out the role of common genetic variation in insulin
resistance in the absence of obesity has been problematic.
There has also been a lack of large cohorts with reliable mea-
sures of insulin sensitivity. Indeed, many measures examine
whole body insulin sensitivity and do not measure insulin
sensitivity at a tissue/organ level. Table 1 lists the loci and
nearby genes associated with insulin resistance identified by
linkage analysis, candidate gene studies and GWAS.
The GENESIS consortium is the only group to date that has
published a GWAS of whole-body insulin sensitivity mea-
sured during hyperinsulinaemia (clamp/insulin suppression
test) in a modest number of subjects (2764 with replication
in an additional 2860 individuals) from four cohorts. The con-
sortium found that variation in NAT2 was associated with
insulin resistance although this did not reach formal
genome-wide significance (rs1208 was associated with de-
creased insulin sensitivity with p = 9.81 × 10−7 after adjusting
for BMI). The rs1208 loci was also associated with fasting
glucose, triglycerides and total cholesterol and with an in-
crease in coronary heart disease risk. A functional relationship
betweenNAT2 and insulin sensitivity was confirmed inmouse
3T3-L1 adipocytes where NAT1 knockdown (the mouse
orthologue of human NAT2) decreased insulin-stimulated
glucose uptake and in a mouse NAT1 knockout model which
showed decreased insulin sensitivity [13].NAT2 is involved in
acetylation and influences sensitivity to certain drugs such as
isoniazid, although the endogenous substrates remain to be
defined (reviewed in [14]). GWAS such as this are challenging
to perform in large cohorts as the protocols involved in mea-
suring whole-body insulin sensitivity are time-consuming,
labour-intensive and, as such, expensive to perform.
The hyperinsulinaemic-euglycaemic clamp is considered
the gold standard method for assessing insulin sensitivity (de-
fined for these purposes as the ability of insulin to stimulate
glucose uptake) but it is a long protocol and complex to per-
form. Simpler measures of insulin sensitivity such as fasting
insulin concentrations and leptin/adiponectin ratios [15] are
often used as a surrogate marker for insulin sensitivity.
Fasting insulin and glucose levels can also be used to calculate
the homeostasis model assessment (HOMA). HOMA-IR is
used as a measure of insulin resistance which has the advan-
tage of being simple to obtain but is not directly comparable to
the clamp measure [16].
In an effort to identify new variants associated with insulin
resistance, large-scale meta-analyses of GWAS have been per-
formed using multiple cohorts which havemeasures of insulin
sensitivity, processing and secretion. This approach has con-
firmed associations of many loci with specific glycaemic traits
as well as identifying new loci. The Meta-Analyses of
Glucose and Insulin-related traits Consortium (MAGIC) per-
formed meta-analyses on GWAS from 21 cohorts of non-
diabetic individuals including 46,186 individuals with mea-
sures of fasting glucose and 38,238 with measures of fasting
insulin and HOMA-IR as an index of insulin resistance.
Twenty-five SNPs were followed up in a further 76,558 indi-
viduals with this approach identifying 16 loci associated with
fasting glucose and two with fasting insulin. This study con-
firmed loci near GCKR and a newly identified loci near IGF1
as being associated with insulin resistance [17] with these
findings being replicated in a further 14 cohorts comprising
29,084 non-diabetic individuals with detailed measures of
fasting proinsulin, insulin secretion and sensitivity [18]. This
latter study has recently been expanded by Dimas and col-
leagues who examined the effect of 37 T2D risk loci on mea-
sures of insulin processing, secretion, sensitivity and clearance
from up to 58,614 non-diabetic individuals with basal mea-
sures and 17,327 individuals with dynamic measures of
glycaemic traits. They found that the risk loci could be
subdivided into five clusters including one cluster with four
loci, PPARγ, KLF14, IRS1 andGCKR, associated with insulin
resistance [19].
More recently, alternate approaches to identifying variants
associated with insulin resistance have been developed.
Manning and colleagues have developed a joint meta-
analysis (JMA) approach to identify SNPs significantly asso-
ciated with either fasting glucose and/or fasting insulin while
Table 1 Variants associated with insulin resistance identified by
candidate gene association studies, linkage analysis and GWAS
SNP Nearby gene Chromosome Ref
rs13081389 PPARG 3 [27, 28]
rs972283 KLF14 7 [29]
rs2943641 IRS1 2 [31]
rs780094 GCKR 2 [17]
rs8050136 FTO 16 [29, 36, 76]
rs7903146 TCF7L2 10 [37, 38]
rs1208 NAT2 8 [13]
rs6723108,
rs998451
TMEM163 2
2
[43]
rs35767 IGF1 12 [17]
rs12970134 MC4R 18 [46, 77]
rs17046216 SC4MOL 4 [48]
rs7077836 TCERG1L 10 [48]
rs702634
rs4311394
ARL15 12 [49, 78]
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both adjusting for BMI and allowing for interaction with BMI
[20]. This analysis method can increase the power to detect
genetic associations where interaction with the environment is
unknown [21, 22]. This approach identified six loci, including
five new variants, as being associated with fasting insulin
levels (IRS1, COBLL1-GRB14, PPP1R3B, PDGFC,
UHRF1BP1 and LYPLAL1). Scott and colleagues used the
Metabochip, a custom genotyping array containing 196,725
SNPs chosen due to their associations with a variety of car-
diometabolic traits including type 2 diabetes, BMI and fasting
glucose [23] and large-scale meta-analyses of up to 133,010
individuals to identify 17 loci significantly associated with
fasting insulin. These loci included those previously identified
by Manning, genes which have previously been associated
with other metabolic traits (TCF7L2, PPARG, FTO, RSPO3,
ANKRD55-MAP3K1 and ARL15) and newly identified loci
(HIP1, TET2, YSK4, PEPD and FAM13A) [24]. These loci
have been used in two further studies to generate an insulin
resistance genetic risk score to examine the relationship be-
tween variants associated with fasting insulin and an individ-
ual’s risk of developing insulin resistance and T2D [25•, 26•].
Scott and colleagues generated an insulin resistance risk score
from ten variants which were also specifically associated with
lower HDL and higher triglycerides (IRS1, GRB14, ARL15,
PPARG, PEPD, ANKRD55-MAP3K1, PDGFC, LYPLAL1,
RSPO3 and FAM13A1) while Yaghootkar and colleagues se-
lected 19 variants to generate their insulin resistance risk
score. These studies found that the insulin resistance genetic
risk score was associated with decreased insulin sensitivity
and lower BMI [25•]. Yaghootkar and colleagues found that
a cluster of 11 risk variants were associated with increased
triglycerides and lower HDL-cholesterol along with a lower
BMI, while individuals with 17 or more of these risk variants
were slimmer but were at higher risk of developing T2D,
coronary artery disease and hypertension compared with those
individuals carrying nine or less of these insulin resistance risk
variants [26•]. Together, these studies highlight that insulin
resistance is not always associated with obesity and can occur
in the absence of a high BMI.
Genetic Loci Associated with Insulin Resistance
Many of the loci that have been identified as being associated
with risk of developing insulin resistance harbour genes near-
by that are good biological candidates for association with
measures of insulin sensitivity. The PPARγ (peroxisome
proliferator-activated receptor gamma) variant Pro12Ala was
one of the first genetic variants to be identified as being repro-
ducibly associated with a decreased risk of developing T2D
[27, 28].PPARγ is a nuclear receptor involved in the transcrip-
tion of genes involved in fatty acid and energy metabolism,
and PPARy agonists are currently used in T2D treatment.
rs972283 near KLF14 (kruppel-like factor 14) was identified
through large-scale association analysis of a European cohort
[29] associated with reduced insulin action, and KLF14 gene
and protein expression have recently been shown to be signif-
icantly reduced in both adipose tissue and muscle from T2D
patients [30]. IRS1 (insulin receptor substrate 1) is a key com-
ponent of the insulin signalling pathway initiating the activa-
tion of PI3K in response to insulin. The C allele at rs2943641
adjacent to IRS1 was identified as being associated with insu-
lin resistance and hyperinsulinaemia in a European popula-
tion. Functional studies showed that the risk allele was asso-
ciated with both lower basal IRS1 protein levels and reduced
PI3K-activity during insulin infusion indicating a causative
role for the variant on disease risk [31]. The SNP,
rs2943650, near IRS1 has also been associated with a lower
body fat percentage, increased triglycerides and insulin resis-
tance, and lower HDL-cholesterol [32]. GCKR (glucokinase
regulator) encodes glucokinase regulatory protein (GKRP)
which binds to, and inhibits the activity of glucokinase, a
key enzyme in regulating hepatic glucose disposal and storage
[33].
Variants within the first intron of FTO were the first to be
robustly linked with bodymass index [34, 35]. Further studies
found significant associations of the variants with obesity-
related traits and also with fasting insulin and insulin sensitiv-
ity [36]. Variants within TCF7L2 (transcription factor 7-like 2)
show the strongest andmost consistent association with risk of
developing T2D of any gene variants identified so far. The risk
variant has been associated with both impaired beta cell func-
tion and insulin resistance [37–39]. Subsequent functional
studies have focussed on the role of TCF7L2 in beta cell
function [40, 41]. However, there is now increasing evidence
for a role for TCF7L2 in insulin-dependent tissues [42]. A
variant in NAT2 (N-acetyltransferase 2) was recently found
to be the top signal in four European cohorts of non-diabetic
individuals who underwent genome-wide genotyping as well
as a direct measure of insulin sensitivity [13]. Functional anal-
ysis of the mouse orthologue, NAT1, demonstrated that NAT1
knockout mice had impaired insulin sensitivity in vivo.
Two loci near TMEM163 (transmembrane protein 163)
were found to be associated with both reduced plasma insulin
and HOMA-IR in a GWAS of a cohort with Indian ancestry
[43]. IGF1 (insulin-like growth factor 1) is similar to insulin in
function and regulates growth and development. Low plasma
levels of IGF-1 have previously been associated with a reduc-
tion in insulin sensitivity [44], and analysis of the rs35767
polymorphism indicates that carriers of the G allele have low-
er circulating levels of IGF-1 compared to A allele carriers
[45]. MC4R (melanocortin 4 receptor) was identified by
GWAS of a UK cohort of Indian-Asian and European ancestry
as being associated with both insulin resistance, as measured
byHOMA-IR and waist circumference, with higher risk-allele
frequencies being found in the Indian-Asian cohort [46].
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Variants within MC4R have also been associated with BMI
[47]. GWAS of an African-American cohort identified the
SNP rs7077836 near TCERG1L (transcription elongation
regulator 1-like) and rs17046216 in SC4MOL (sterol-C4-
methyl oxidase-like) as being associated with both fasting
insulin and HOMA-IR, a finding also replicated in a West
African cohort [48]. ARL15 (ADP ribosylation factor like
GTPase 15) belongs to a family of intracellular vesicle traf-
ficking although its exact function is still unknown. Variants
within ARL15 are associated with decreased adiponectin
levels and nominally associated with risk of T2D, coronary
heart disease and insulin resistance asmeasured byHOMA-IR
[49]. Adiponectin is an adipokine involved in improving in-
sulin sensitivity (reviewed in [50]). A recent study using a
novel adiponectin receptor agonist suggests that activation of
the adiponectin pathway directly improves insulin sensitivity
[51].
Some of the novel loci are of unknown function but others,
such as PPP1R3B (protein phosphatase 1 regulatory subunit
3B), are thought to play a role in skeletal muscle glycogen
synthesis [52] while GRB14 (growth factor receptor bound
protein 14) interacts with receptor tyrosine kinases such as
the insulin and insulin-like growth factor receptors [53].
Common Genetic Variation in Metabolic Syndrome
The search for genetic determinants of the metabolic syn-
drome has largely taken two approaches, either examin-
ing the metabolic syndrome as a whole or as pairs of
traits, or analysing associations with the individual com-
ponents of the metabolic syndrome. Before GWAS, can-
didate gene association studies and linkage studies re-
ported a number of potential genes associated with as-
pects of the metabolic syndrome but many of these find-
ings were not replicated. Most GWAS to date have ex-
amined associations of variants with the individual com-
ponents of the metabolic syndrome with at least 56 loci
being reproducibly associated with obesity, 157 with
lipids and over 90 loci associated with hypertension as
well as the numerous loci associated with T2D (reviewed
in [54]). It is beyond the scope of this review to discuss
GWAS associated with the individual metabolic syn-
drome components. Instead, we focus on summarizing
GWAS involving the examination of the metabolic syn-
drome as an entity in itself. Table 2 summarizes the
variants identified in such studies.
The first GWAS examining common genetic variation
in metabolic syndrome was performed on a population of
Indian-Asian men who have a higher prevalence of meta-
bolic syndrome compared to the European population. A
total of approximately 317,000 SNPs were genotyped in
2700 individuals in stage 1 with the top 1500 SNPs
followed up in 2300 individuals in stage 2. No common
genetic basis for metabolic syndrome was identified in
this study [55]. GWAS of a European population exam-
ined the association of approximately 2.5 million SNPs
with either metabolic syndrome as a whole, or with pairs
of traits in 22,161 individuals. Variants near BUD13,
ZNF259, APOA5, LPL and CETP were found to be asso-
ciated with metabolic syndrome, and a further 27 variants
were associated with combinations of pairs of traits [56].
Avery and colleagues adopted a different approach to ex-
amining the metabolic syndrome involving the clustering
of metabol ic t ra i ts into six phenotype domains
encompassing 19 quantitative traits. Using data from 19,
486 European and 6287 African-American individuals,
they identified three new loci associated with more than
one phenotype domain, APOC1, BRAP and PLCG1 as
well as confirming associations of variants near GCKR,
ABCB11, LPL, HNF1A, FTO and SUGP1 with multiple
phenotype domains [57]. A study in four Finnish cohorts
encompassing 11,616 individuals identified a SNP,
rs964184, near the APOA1/C3/A4/A5 gene cluster on
chromosome 11 as being associated with metabolic syn-
drome confirming a strong lipid gene component to the
genetics of the metabolic syndrome [58]. Three GWAS
Table 2 Common genetic variation associated with the metabolic
syndrome
SNP Nearby gene Chromosome Ref
rs295
rs10790162
rs2075290
rs2266788
rs173539
LPL
BUD13
ZNF259
APOA5
CETP
8
11
11
11
16
[56]
rs4420638
rs11065987
rs753381
rs1260326
rs579060
rs301
rs7979473
rs9923233
rs10401969
APOC1
BRAP
PLCG1
GCKR
ABCB11
LPL
HNF1A
FTO
SUGP1
19
12
20
2
2
8
12
16
19
[57]
rs964184 APOA1/C3/A4/A5 11 [58]
rs11216126
rs180349
BUD13
BUD13
11
11
[59]
rs12721054 APOC1 19 [60]
rs73989312
rs73989319
rs7964157
rs77244975
rs76822696
rs16912410
rs62526240
rs55752635
rs146816516
CA10
CA10
KSR2
CTNNA3
RALYL
RALYL
RALYL
RALYL
MBNL1
17
17
12
10
8
8
8
8
3
[61]
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studies have examined association of genetic variants in
non-European populations. A study of 8842 Korean indi-
viduals identified two SNPs near BUD13 as reaching
genome-wide significance with a further eight SNPs re-
ported to be of nominal significance including previously
reported variants near APOA5 and LPL [59]. Metabochip
genotype array analysis of an African-American popula-
tion identified 27 SNPs associated with the metabolic syn-
drome; however, only one (APOC1) was associated with
all five components of the metabolic syndrome [60]. More
recently, GWAS on a population of African ancestry iden-
tified variants near RALYL, KSR2, MBNL1 and two vari-
ants specific to the African population near CA10 and
CTNNA3 as being associated with metabolic syndrome
[61].
While there is limited overlap between these GWAS,
which may, at least in part, be due to slight differences in
the definition of metabolic syndrome used, it is notable
that many of the identified genes are associated with lipid
traits. For example, variants near ZNF259, APOB, LPL,
APOA5, CETP and GCKR have been previously shown to
be associated with either low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol or triglycerides
[62]. Overall, these studies indicate that while there may
be a strong lipid element to the genetics underlying the
metabolic syndrome, there is no clear evidence at this
point in time of one or more pathways linking the differ-
ent aspects of the syndrome. In a different approach to
identify if common metabolic pathways link the various
components of the metabolic syndrome, data from 1193
twin men from the Vietnam Era Twin Study of Aging
with measures of adiposity (body mass index and waist
circumference), blood pressure, insulin resistance (fasting
insulin and glucose) and lipids (high-density lipoprotein
cholesterol and triglycerides) were analysed [63]. This
study suggested that adiposity may be the underlying fac-
tor which links the other factors in the metabolic syn-
drome with findings indicating shared genetic influences
between insulin resistance, lipids and adiposity and also
between blood pressure and adiposity.
Low-Frequency and Rare Variants
Despite the increased success in identifying risk loci as-
sociated with insulin resistance and T2D, it has been
estimated that these common variants account for only
25–44 % of the heritability of insulin resistance
[64–66]. The contribution of low-frequency (MAF ≤
5 %) and rare variants (MAF ≤ 0.5 %) to the heritability
of T2D and the metabolic syndrome remains to be ex-
plored. Exome sequencing, where all protein-coding
genes in the genome are sequenced to document all
genetic variation in these regions, has recently been
employed in an effort to identify novel low-frequency
variants that may have large effects on common metabol-
ic phenotypes. Exome sequencing in a Danish cohort of
2000 individuals with a follow-up in a further 15,989
individuals revealed associations of two common SNPs
within COBLL1 and MACF1 with T2D and a low-
frequency variant in CD300LG with fasting HDL-
cholesterol [67]. While the biological function of the
variants within COBLL1 and MACF1 is unknown, explo-
ration of the functional effects of the risk variant
rs72836561 at CD300LG revealed that this polymor-
phism is associated with reduced mRNA expression of
CD300LG in skeletal muscle and adipose tissue, de-
creased insulin sensitivity and increased intramyocellular
lipid content suggesting a link between this variant and
aspects of the metabolic syndrome [68]. Exome sequenc-
ing in an Icelandic population revealed that a low-
frequency variant in CCND2 reduces the risk of devel-
oping T2D but, counterintuitively, is also associated with
higher body mass index [69].
The 1000 Genomes Project was established to se-
quence, through a combination of both genome and ex-
ome sequencing, the genomes of 1092 individuals to aid
identification of low-frequency and rare genetic variants
across populations [70]. These reference panels, contain-
ing 38 million SNPs, have been used by the European
Network for Genetic and Genomic Epidemiology
(ENGAGE) consortium to successfully impute the geno-
types of low-frequency variants and perform 22 GWAS
for BMI, waist-hip ratio, fasting glucose and fasting insu-
lin. A meta-analysis of these imputed GWAS identified
two novel loci for BMI and two novel loci for fasting
glucose, of which one was female-specific. The investiga-
tors also identified new lead SNPs at 29 established ge-
netic loci including rs1260326 near GCKR for fasting in-
sulin [71].
Another approach to identifying genetic variation asso-
ciated with complex traits is to examine small populations
which have been historically isolated. Such populations
are often referred to as founder populations. Genotyping
of 2733 individuals from the Greenlandic population
using the Cardio-Metabochip followed by exome se-
quencing identified a common variant within TBC1D4
as being associated with higher fasting glucose and re-
duced insulin sensitivity [72]. The effect of this
p.Arg684Ter variant is to disrupt expression of the full-
length TBC1D4 protein in skeletal muscle resulting in
decreased insulin-stimulated glucose uptake.
Individuals with familial partial lipodystrophy appear
predisposed to features of the metabolic syndrome and insulin
resistance. Familial partial lipodystrophy tends to be associat-
ed with functional mutations in the LMNA (lamin A/C) gene
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[73] resulting in altered adipose tissue distribution. Genetic
mutations, affecting either LMNA or the associated processing
enzyme ZMPSTE24, have been shown to have a prevalence of
3 % in a small cohort of patients with metabolic syndrome
[74] raising the possibility that mutations in the LMNA gene
may contribute, or predispose, an affected individual to the
metabolic syndrome.
Future approaches in identifying low-frequency and rare
variants include the UK10K-cohort project which has com-
bined whole-genome sequencing in a cohort of 3781 healthy
individuals with exome sequencing of 6000 individuals with
either rare disease, severe obesity or a neurodevelopmental
disorder [75•]. This project has uncovered 24 million novel
genetic variants and resulted in the generation of reference
panels with increased coverage of low-frequency and rare
variants to help facilitate the identification and contribution
of rare variants in health and disease.
Summary and Future Directions
Considerable recent progress has been made in the identifica-
tion of genetic loci that are associated with insulin resistance
and the metabolic syndrome. Some are directly involved in
insulin action and glucose metabolism, while further work is
required to determine the functional relationships between the
genetic variants and insulin action. Nonetheless, the identifi-
cation of validated variants has been challenging for a number
of reasons. First, it is evident that the phenotypes (insulin
resistance and metabolic syndrome) are influenced by lifestyle
and environmental factors which need to be taken into account
when exploring the underlying genetic architecture of these
traits. Second, the insulin resistance phenotype itself is diffi-
cult to quantify, often relying upon indirect measures such as
circulating insulin levels. Furthermore, the phenotype is often
limited to whole body measurements with no comprehensive
analysis of genetic variants influencing tissue-specific insulin
resistance.
Despite these concerns, our appreciation of the genetic ba-
sis of insulin resistance and metabolic syndrome has evolved
through a number of approaches described in this review. The
challenge moving forward is to translate this knowledge into
clinical practice to help predict and manage related conditions
such as type 2 diabetes and cardiovascular disease.
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